|
EQS-News: STRATEC SE / Key word(s): Personnel STRATEC REPORTS CHANGES IN FINANCE DIVISION 30.07.2024 / 09:55 CET/CEST The issuer is solely responsible for the content of this announcement. STRATEC REPORTS CHANGES IN FINANCE DIVISION Birkenfeld, July 30, 2024 STRATEC SE, a leading manufacturer of automation solutions for partners in clinical diagnostics and life sciences, is reporting a change in the composition of its Board of Management. In agreement with the company, Dr. Robert Siegle, a member of the Board of Management of STRATEC SE, will stand down from his position on the Board of Management and leave the company as of August 31, 2024. Prof. Dr. Georg Heni, Chairman of the Supervisory Board, thanks Dr. Robert Siegle on behalf of STRATEC SE for his longstanding and successful commitment to the company. During his time as a member of the Board of Management, Dr. Siegle has made a major contribution to the company’s successful development. Dr. Siegle’s tasks will be performed by Oliver Albrecht, who will act in the capacity of an interim CFO. Oliver Albrecht has a long track record of experience and great expertise in leading finance departments at listed technology companies with an international focus. He was most recently Chief Financial Officer at the listed company SÜSS MicroTec SE from 2019 to 2023. ABOUT STRATEC The partners market the systems, software, and consumables, in general together with their own reagents, as system solutions to laboratories, blood banks, and research institutes around the world. STRATEC develops its products on the basis of patented technologies. Shares in the company (ISIN: DE000STRA555) are traded in the Prime Standard segment of the Frankfurt Stock Exchange and are listed in the SDAX select index of the German Stock Exchange. FURTHER INFORMATION IS AVAILABLE FROM: 30.07.2024 CET/CEST Dissemination of a Corporate News, transmitted by EQS News – a service of EQS Group AG. The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. |
MU researcher receives $3 million grant to use gene editing for investigating the building blocks of disease
In a new study funded by a $3 million grant from the National Institutes of Health (NIH), University of Missouri researcher Kiho Lee, an associate
July 27, 2023